REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

UnicoCell Biomed Co., Ltd. (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: UnicoCell Biomed Co., Ltd. Profile Updated: July 08, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

UnicoCell Biomed Co., Ltd. is focused on the research & development of drugs and techniques on stem cell. The company was established in 2018, headquartered in Taipei City, Taiwan.

Headquarters
5 F., No. 13-20, Sec. 6, Minquan E. Rd, Neihu Dist
Taipei City; Taipei City;

Contact Details: Purchase the UnicoCell Biomed Co., Ltd. report to view the information.

Website: http://www.unicocell.com

Basic Information
Total Employees:
Purchase the UnicoCell Biomed Co., Ltd. report to view the information.
Outstanding Shares:
Purchase the UnicoCell Biomed Co., Ltd. report to view the information.
Financial Auditors:
Purchase the UnicoCell Biomed Co., Ltd. report to view the information.
Incorporation Date:
March 28, 2018
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
General Manager
Ownership Details
Purchase this report to view the information.
18.73%
Purchase this report to view the information.
14.42%
Purchase this report to view the information.
4.85%
Purchase this report to view the information.
4.1%
Purchase this report to view the information.
Subsidiaries
Cytotreat Co., Ltd.
Company Performance
Financial values in the chart are available after UnicoCell Biomed Co., Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
-46.57%▼
Total operating revenue
-10.18%▼
Operating profit (EBIT)
-45.73%▼
EBITDA
-113.38%▼
Net Profit (Loss) for the Period
-74%▼
Total assets
10.29%▲
Total equity
12.06%▲
Operating Profit Margin (ROS)
-594.75%▼
Net Profit Margin
-625.07%▼
Return on Equity (ROE)
-2.84%▼
Quick Ratio
-1.3%▼
Cash Ratio
-1.72%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo